EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

08 Jul 2025 15:45:24 By Nasdaq GlobeNewswire

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

02 Jul 2025 15:05:19 By Nasdaq GlobeNewswire

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

23 Jun 2025 07:05:07 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Addition to Russell 3000® Index

20 Jun 2025 07:13:29 By Nasdaq GlobeNewswire

Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

05 Jun 2025 06:00:21 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Upcoming Investor Conferences

14 May 2025 06:32:11 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports First Quarter 2025 Financial Results

07 May 2025 15:05:02 By Nasdaq GlobeNewswire

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

01 May 2025 16:07:20 By Nasdaq GlobeNewswire

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

22 Apr 2025 06:59:59 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Stock Repurchase Program

31 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

20 Mar 2025 15:30:00 By Nasdaq GlobeNewswire

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

20 Mar 2025 07:06:17 By Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

19 Mar 2025 15:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

18 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

13 Mar 2025 07:29:43 By Nasdaq GlobeNewswire

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

12 Mar 2025 07:00:26 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

10 Mar 2025 08:14:36 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

03 Mar 2025 15:23:25 By Nasdaq GlobeNewswire

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

18 Feb 2025 07:55:56 By Nasdaq GlobeNewswire

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

07 Feb 2025 07:06:54 By Nasdaq GlobeNewswire